(Q33862829)

29 July 2017

title

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer (English)

1 reference

29 July 2017

1 reference

5

Yehuda Z Patt

1 reference

29 July 2017

Steven J Cohen

1

1 reference

29 July 2017

Mark M Zalupski

2

1 reference

29 July 2017

Manuel R Modiano

3

1 reference

29 July 2017

Paul Conkling

4

1 reference

29 July 2017

Peg Davis

6

1 reference

29 July 2017

Robert T Dorr

7

1 reference

29 July 2017

Michelle L Boytim

8

1 reference

29 July 2017

Evan M Hersh

9

1 reference

29 July 2017

publication date

24 October 2009

1 reference

Cancer Chemotherapy and Pharmacology

29 July 2017

published in

1 reference

29 July 2017

volume

66

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

287-294

1 reference

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

5 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Preclinical, pharmacologic, and phase I studies of gemcitabine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873145

Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19855966

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I trial of imexon in patients with advanced malignancy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19855966

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-009-1162-Y

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference